TPN171

Phosphodiesterase type 5 (PDE5) inhibitors

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

1.	Pulmonary Arterial Hypertension 01/01/2023 - "Pharmacokinetics, mass balance, and metabolism of [14C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension." 01/01/2019 - "Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension." 01/01/2023 - "TPN171 is a novel phosphodiesterase-5 (PDE5) inhibitor used to treat pulmonary arterial hypertension (PAH) and erectile dysfunction (ED), which currently is undergoing phase II clinical trials in China. "
2.	Erectile Dysfunction 01/01/2023 - "TPN171 is a novel phosphodiesterase-5 (PDE5) inhibitor used to treat pulmonary arterial hypertension (PAH) and erectile dysfunction (ED), which currently is undergoing phase II clinical trials in China. "
3.	Heart Diseases (Heart Disease) 08/01/2020 - "To develop PET tracers for imaging of heart disease, a new carbon-11 labeled potent and selective PDE5 inhibitor [11C]TPN171 ([11C]9) has been synthesized. "

1.	Phosphodiesterase 5 Inhibitors
2.	Type 5 Cyclic Nucleotide Phosphodiesterases
3.	Carbon-11